☆ 4.7 Article

RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Get Full Text
Add to Collection

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 36_suppl, Pages 384950-384950

Publisher

American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2022.40.36_suppl.384950

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.